1-(3-chlorophenyl)-4-(1-methylethyl)piperazine | 141510-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-chlorophenyl)-4-(1-methylethyl)piperazine
• 英文别名: 1-(3-Chloro-phenyl)-4-isopropyl-piperazine；1-(3-chlorophenyl)-4-propan-2-ylpiperazine
• CAS: 141510-95-4
• 化学式: C₁₃H₁₉ClN₂
• 分子量: 238.76
• InChiKey: FWDNWHLUDLUDBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  338.8±37.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴丙烷 、 1-(3-氯苯基)哌嗪 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 8.0h， 生成 1-(3-chlorophenyl)-4-(1-methylethyl)piperazine
  参考文献：
  名称：

  中枢神经系统制剂的结构活性关系研究。5.烃链对4-取代的1-（3-氯苯基）哌嗪对5-HT1A受体位点的亲和力的影响。

  摘要：

  研究了模型4-取代的1-（3-氯苯基）哌嗪12-31的烃链对其对5-HT1A受体位点的亲和力的影响。发现4-正烷基链的延长强烈增加了所研究化合物的5-HT1A亲和力。正己基衍生物20的亲和力达到最大值（Ki ＝ 2.67nM）。已表明1-芳基哌嗪的N-4取代基的疏水相互作用显着地促进了它们的5-HT1A亲和力。特异性结合常数定义为在生理条件下化合物的质子化物质的受体亲和力。Ki（AH +）的范围为1-3 x 10（-11）M是在5-HT1A受体位点上所研究化合物类别的特定亲和力极限。

  DOI：

  10.1021/jm00091a004

文献信息

• THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS
  申请人：Fink M. David

  公开号：US20070004695A1

  公开（公告）日：2007-01-04

  The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D 4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D 4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

  这些化合物属于类别为噻唑异噁唑基和噻吩吡唑基苯氧基取代的丙基衍生物，可用作D4受体拮抗剂。这些化合物可用于治疗通过抑制D4受体介导的医疗状况。这些状况包括例如注意力缺陷多动障碍、强迫症、精神病、物质滥用、物质依赖、帕金森病、帕金森综合症、迟发性运动障碍、吉尔·德·拉·图雷特综合症、行为障碍和反抗行为障碍。发明的另一个方面是提供一种制药组合物、中间体和制备该类化合物的方法。
• INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS
  申请人：Liu Jun O.

  公开号：US20120196852A1

  公开（公告）日：2012-08-02

  The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.

  该发明涉及新型萘醌和萘噻唑化合物，以及使用各种萘醌、羟基萘醌和萘噻唑化合物治疗与MetAP相关的疾病，包括结核病和细菌感染的方法。
• Inhibitors of methionine aminopeptidases and methods of treating disorders
  申请人：Liu Jun O.

  公开号：US10472315B2

  公开（公告）日：2019-11-12

  The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.

  本发明涉及新型萘醌和萘噻唑化合物，以及使用各种萘醌、羟基醌和萘噻唑化合物治疗与 MetAP 有关的疾病（包括结核病和细菌感染）的方法。
• Aryl cyclopropyl-amino-isoquinolinyl amide compounds
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US10858339B2

  公开（公告）日：2020-12-08

  Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

  本文提供的是芳基环丙基氨基异喹啉酰胺化合物。特别是，本公开提供的化合物可影响细胞中激酶的功能，并可作为治疗剂或与治疗剂一起使用。本公开的化合物可用于治疗多种疾病和病症，包括眼部疾病（如青光眼）、心血管疾病、以异常生长为特征的疾病（如癌症）以及炎症性疾病。本公开进一步提供了含有异喹啉酰胺化合物的组合物。
• ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20210002253A1

  公开（公告）日：2021-01-07

  Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.